# US 2026/0061046 A1 · Combination Vaccine For Prevention Of Influenza And Coronavirus Infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061046 A1
- Document ID: US20260061046A1
- Status: Published application
- Kind: A1
- Application number: 19/382,507
- Filed: 2025-11-07
- Published: 2026-03-05
- Earliest claimed: 2023-05-10
- Assignees: National University Corporation Hokkaido University; KM Biologics Co., Ltd.
- Applicants: National University Corporation Hokkaido University; KM Biologics Co., Ltd.
- Inventors: Masashi SHINGAI; Hiroshi KIDA; Kazumasa OGASAWARA; Masafumi ENDO; Minako OKUMURA; Toshiaki NAGASATO
- Web page: https://patentgrep.com/patent/US20260061046A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

## Claims

### Claim 1

A combination vaccine comprising an inactivated whole particle influenza vaccine and an inactivated whole particle SARS-COV-2 vaccine.

### Claim 2 (depends on 1)

The combination vaccine according to claim 1 which does not containing an adjuvant.

### Claim 3 (depends on 1)

The combination vaccine according to claim 1, wherein the inactivated whole particle influenza vaccine comprises an inactivated whole particle influenza vaccine against two or more influenza virus strains.

### Claim 4 (depends on 2)

The combination vaccine according to claim 2, wherein the inactivated whole particle influenza vaccine comprises an inactivated whole particle influenza vaccine against two or more influenza virus strains.

### Claim 5 (depends on 3)

The combination vaccine according to claim 3, wherein the inactivated whole particle influenza vaccine is a quadrivalent inactivated whole particle influenza vaccine using, as vaccine strains, two type A virus strains and two type B virus strains.

### Claim 6 (depends on 4)

The combination vaccine according to claim 4, wherein the inactivated whole particle influenza vaccine is a quadrivalent inactivated whole particle influenza vaccine using, as vaccine strains, two type A virus strains and two type B virus strains.

### Claim 7 (depends on 1)

The combination vaccine according to claim 1, wherein the inactivated whole particle influenza vaccine and/or the inactivated whole particle SARS-COV-2 vaccine is the whole influenza virus and/or the whole SARS-COV-2 virus which has been inactivated by formaldehyde.

### Claim 8 (depends on 2)

The combination vaccine according to claim 2, wherein the inactivated whole particle influenza vaccine and/or the inactivated whole particle SARS-COV-2 vaccine is the whole influenza virus and/or the whole SARS-COV-2 virus which has been inactivated by formaldehyde.

### Claim 9

A method for prevention of influenza infection and COVID-19 in a subject, comprising administrating to the subject a combination vaccine which comprises an inactivated whole particle influenza vaccine and an inactivated whole particle SARS-COV-2 vaccine.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the combination vaccine does not containing an adjuvant.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the inactivated whole particle influenza vaccine comprises an inactivated whole particle influenza vaccine against two or more influenza virus strains.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the inactivated whole particle influenza vaccine comprises an inactivated whole particle influenza vaccine against two or more influenza virus strains.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the inactivated whole particle influenza vaccine is a quadrivalent inactivated whole particle influenza vaccine using, as vaccine strains, two type A virus strains and two type B virus strains.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the inactivated whole particle influenza vaccine is a quadrivalent inactivated whole particle influenza vaccine using, as vaccine strains, two type A virus strains and two type B virus strains.

### Claim 15 (depends on 9)

The method according to claim 9, wherein the inactivated whole particle influenza vaccine and/or the inactivated whole particle SARS-COV-2 vaccine is the whole influenza virus and/or the whole SARS-COV-2 virus which has been inactivated by formaldehyde.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the inactivated whole particle influenza vaccine and/or the inactivated whole particle SARS-COV-2 vaccine is the whole influenza virus and/or the whole SARS-COV-2 virus which has been inactivated by formaldehyde.

### Claim 17

A combination of an inactivated whole particle influenza vaccine and an inactivated whole particle SARS-COV-2 vaccine, wherein the inactivated whole particle influenza vaccine and the inactivated whole particle SARS-COV-2 vaccine are mixed at the time of using the combination and is administered to a subject as a combination vaccine for prevention of influenza infection and COVID-19.

### Claim 18 (depends on 17)

The combination according to claim 17, wherein neither the inactivated whole particle SARS-COV-2 vaccine nor the inactivated whole particle influenza vaccine contains an adjuvant.

### Claim 19 (depends on 17)

A kit comprising the combination according to claim 17, wherein the inactivated whole particle influenza vaccine and the inactivated whole particle SARS-COV-2 vaccine are charged into different vials.

### Claim 20 (depends on 19)

The kit according to claim 19, wherein neither the inactivated whole particle SARS-COV-2 vaccine nor the inactivated whole particle influenza vaccine contains an adjuvant.
